John Olowoyeye
Cardiovascular Disease · Stockton, CANPI 1336256726
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.6% of the total across 289 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 33 manufacturers, the largest accounting for just 11.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,946 and has fallen 96.7% since, to $65 in 2023.
Across 289 payments — averaging $19.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$662
- Sanofi-aventis U.S. LLC$475
- Johnson & Johnson$468
- Bayer$404
- E.r. Squibb & Sons, L.L.C.$393
- AstraZeneca$377
- plus $3K from 27 others
What the payments were for
- Food & beverage$5,50197%
- Education$1963%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 31 | $662 |
| Sanofi-aventis U.S. LLC | 25 | $475 |
| Johnson & Johnson | 29 | $468 |
| Bayer | 20 | $404 |
| E.r. Squibb & Sons, L.L.C. | 18 | $393 |
| AstraZeneca | 21 | $377 |
| Boehringer Ingelheim | 23 | $368 |
| Amgen | 20 | $356 |
| Shockwave Medical, Inc | 5 | $326 |
| Kowa Pharmaceuticals America, Inc. | 16 | $306 |
| Pfizer | 13 | $227 |
| Esperion Therapeutics, Inc. | 13 | $161 |
| Abiomed | 1 | $143 |
| Regeneron Healthcare Solutions, Inc. | 8 | $135 |
| Merck | 7 | $131 |
| Elutia, Inc. | 7 | $127 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 6 | $104 |
| Abbott | 4 | $88 |
| Novo Nordisk | 1 | $52 |
| Irhythm Technologies, Inc. | 2 | $47 |
| Kiniksa Pharmaceuticals, Ltd. | 2 | $46 |
| Boston Scientific | 3 | $44 |
| Vifor Pharma, Inc. | 2 | $39 |
| Preventice Services, LLC | 2 | $36 |
| Actelion Pharmaceuticals US, Inc. | 1 | $36 |
| Otsuka America Pharmaceutical, Inc. | 2 | $32 |
| Biotronik Inc. | 1 | $24 |
| Portola Pharmaceuticals, LLC | 1 | $21 |
| Medtronic | 1 | $19 |
| Bardy Diagnostics, Inc. | 1 | $13 |
| AbbVie | 1 | $13 |
| Impulse Dynamics (USA) Inc. | 1 | $13 |
| Amarin Pharma, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Legacy$143
- Vascular Lithotripsy$120
- Kerendia$118
- ENTRESTO$101
How this compares
$5,697 in reported general payments places this provider in the 65th percentile of 2,184 cardiovascular disease providers in California.
Other cardiovascular disease in Stockton
- Daren PrimackStockton$234K
- Ted LoveHillsborough$102.8M
- Paul KurthSanta Barbara$6.1M
- Jason RogersSacramento$4.4M
- Matthew BudoffTorrance$3.6M
- Eric Topolla Jolla$2.2M
- Cathleen Bairey-MerzLos Angeles$1.2M
- Gagan SinghSacramento$1.2M
- Pam Taubla Jolla$1.2M
- Wilber SuStanford$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.